What are the recommended next‑line treatment options for a patient with refractory myasthenia gravis who remains uncontrolled despite optimal pyridostigmine, high‑dose prednisone (1 mg/kg daily), and a conventional steroid‑sparing agent such as azathioprine or mycophenolate mofetil?

Refractory Myasthenia Gravis: Next-Line Treatment Options

For patients with refractory myasthenia gravis failing pyridostigmine, high-dose prednisone, and conventional steroid-sparing agents (azathioprine or mycophenolate), rituximab should be your first choice for next-line therapy, particularly in MuSK-antibody positive patients, followed by consideration of the newer FDA-approved agents eculizumab, efgartigimod, or ravulizumab for AChR-antibody positive disease.

Treatment Algorithm for Refractory Disease

First: Verify True Refractoriness

Before escalating therapy, confirm:

• Adequate dosing and duration: Azathioprine requires ≥2 mg/kg/day for at least 12 months; mycophenolate mofetil needs ≥2 g/day for at least 8 months 1
• Antibody status: AChR-positive versus MuSK-positive disease responds differently to therapies 2
• Thymectomy consideration: If not yet performed and patient is under 50-65 years without thymoma, or any age with thymoma 3

Second: Choose Next-Line Agent Based on Antibody Status

For MuSK-antibody positive patients:

• Rituximab is the preferred option despite lacking high-quality RCT evidence, as clinical experience demonstrates particular efficacy in this subgroup 2
• Targets CD20+ B cells, addressing the underlying pathophysiology more directly in MuSK-MG

For AChR-antibody positive patients, three FDA-approved options:

1. Eculizumab (complement C5 inhibitor)

   • Approved for refractory generalized MG in AChR-positive adults 2
   • Critical caveat: Mandates meningococcal vaccination due to Neisseria meningitidis risk 4
   • Rapid onset of action with selective immunotherapy

2. Efgartigimod (FcRn inhibitor)

   • Recently FDA-approved for AChR-positive generalized MG 2
   • Prevents IgG recycling, causing rapid antibody reduction 4
   • Promising safety profile with fewer systemic side effects

3. Ravulizumab (long-acting complement C5 inhibitor)

   • FDA-approved alternative to eculizumab 2
   • Less frequent dosing than eculizumab
   • Same meningococcal vaccination requirement

Third: Alternative Options

Rituximab for AChR-positive disease:

• Reasonable option even in AChR-positive patients when novel agents are unavailable or cost-prohibitive 5
• Established clinical experience despite limited RCT data

High-dose cyclophosphamide:

• Reserved for severe refractory cases 5
• Significant toxicity profile limits routine use

Repeat thymectomy:

• Consider in selected patients with previous thymectomy who remain refractory 5

Critical Decision Points

Cost and Access Considerations

The novel biologicals (eculizumab, efgartigimod, ravulizumab) are highly effective but expensive. Access depends on local availability, insurance coverage, and cost-benefit analyses 3. When these agents are not accessible, rituximab remains a viable and more affordable option.

Bridging Therapy

While initiating any of these agents, continue:

• IVIG or plasma exchange for acute exacerbations or crisis management 3, 2
• Maintain corticosteroids at lowest effective dose during transition

Monitoring Requirements

For complement inhibitors (eculizumab, ravulizumab):

• Complete meningococcal vaccination series at least 2 weeks before initiation
• Monitor for signs of meningococcal infection throughout treatment
• Consider antibiotic prophylaxis in high-risk patients

For FcRn inhibitors (efgartigimod):

• Monitor IgG levels
• Watch for increased infection risk with prolonged use

For rituximab:

• Monitor B-cell counts
• Screen for hepatitis B reactivation
• Watch for infusion reactions

Common Pitfalls to Avoid

1. Premature escalation: Many patients labeled "refractory" simply haven't received adequate doses or duration of conventional agents 1. Azathioprine toxicity is common (66% develop reactions) but often manageable with dose adjustment rather than discontinuation 6.

2. Ignoring antibody status: MuSK-positive patients respond differently than AChR-positive patients. Don't apply the same algorithm to both 2.

3. Forgetting vaccination: Starting complement inhibitors without meningococcal vaccination is dangerous and potentially fatal 4.

4. Overlooking thymectomy: Even in "refractory" disease, thymectomy can improve outcomes in appropriate candidates and should be reconsidered 2.

Practical Implementation

Start with rituximab if cost is a barrier or patient is MuSK-positive. Choose novel biologicals (eculizumab, efgartigimod, or ravulizumab) for AChR-positive patients when accessible, prioritizing based on local formulary availability and patient-specific factors (dosing frequency preferences, vaccination status, insurance coverage).

The landscape of MG treatment has expanded considerably, but successful management still requires combining interventions appropriately and maintaining long-term specialized follow-up 3. Most refractory patients will achieve meaningful improvement with these advanced therapies, though complete remission remains elusive for some.